Comment
Author: Admin | 2025-04-28
Pneumonia (up to 20%), cough (up to 19%), epistaxis (up to 15.8%), dyspnea (up to 14.9%), COVID-19 (up to 14%), nasopharyngitis (up to 10.9%)Common (1% to 10%): Influenza, lower respiratory tract infection, bronchitisFrequency not reported: Respiratory tract infection, pleural effusion, lung infectionUpper respiratory tract infection included upper respiratory tract infection, viral upper respiratory tract infection, laryngitis, nasopharyngitis, sinusitis, rhinitis, pharyngitis, rhinovirus infection, upper respiratory tract congestion, tonsillitis, upper respiratory tract inflammation, and related terms.Pneumonia included pneumonia, fungal pneumonia, cryptococcal pneumonia, streptococcal pneumonia, atypical pneumonia, lung infection, lower respiratory tract infection, bacterial lower respiratory tract infection, viral lower respiratory tract infection, lung infiltration, aspiration pneumonia, viral pneumonia, COVID-19 pneumonia, bronchopulmonary aspergillosis, organizing pneumonia, and related terms (including specific types of infection).Cough included cough and productive cough.COVID-19 included COVID-19, COVID-19 pneumonia, post-acute COVID-19 syndrome, and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test.References1. Cerner Multum, Inc. "UK Summary of Product Characteristics."2. (2023) "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, SUPPL-103. (2023) "Product Information. Brukinsa (zanubrutinib)." Beigene Aus Pty LtdFrequently asked questionsWhat are the names of the BTK inhibitors?Further informationZanubrutinib side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.Medical Disclaimer
Add Comment